Replies to post #85470 on Biotech Values

[DewDiligence]

AZN can’t catch a break, it seems. They must be the unluckiest Big Pharma other than PFE.

[DewDiligence]

ODAC votes 10-0 that AZN’s vandetanib (a/k/a Zactima/ZD6474) for thyroid cancer should have a post-marketing study to find the best dose:

http://www.reuters.com/article/idUSN0222054620101202?feedType=RSS&feedName=governmentFilingsNews&rpc=43

Although the panel did not explicitly vote on whether the FDA should approve vandetanib for marketing, I interpret the vote on a post-marketing study to be an implicit vote for approval.